China Resources Boya Bio-pharmaceutical Issues Sharp 2025 Profit Warning After Acquisition
China Resources Boya Bio-pharmaceutical, a key player in blood products and medical aesthetics, has warned of a steep profit drop for 2025, projecting net profit attributable to shareholders at